Bristol Myers Squibb (BMS) has agreed to a research and licensing deal with Prime Medicine to develop ex vivo T cell therapies. Under the terms of the deal announced yesterday (30 September), ...

Bristol Myers Squibb has had a whiplash change of heart on its BCMA bispecific T-cell engager, halting (PDF) further development months after filing to run a phase 3 trial. The Big Pharma disclosed ...

Bristol Myers Squibb has released a very top-line look at the first late-stage data for a lymphocyte-activation gene 3 (LAG-3) asset, but with no actual figures there’s a lag before we find out just ...

Bristol Myers Squibb (BMS) has reported a first-in-class win for its PD-1 inhibitor Opdivo after the immunotherapy demonstrated positive results in resectable, pre-surgery non-small cell lung cancer ...